Logo image of NBIX

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Price, Quote, News and Overview

NASDAQ:NBIX - Nasdaq - US64125C1099 - Common Stock - Currency: USD

110.95  +1.27 (+1.16%)

NBIX Quote, Performance and Key Statistics

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (5/5/2025, 12:07:02 PM)

110.95

+1.27 (+1.16%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High157.98
52 Week Low84.23
Market Cap10.98B
Shares98.94M
Float96.83M
Yearly DividendN/A
Dividend YieldN/A
PE33.72
Fwd PE26.48
Earnings (Next)05-05 2025-05-05/amc
IPO05-23 1996-05-23


NBIX short term performance overview.The bars show the price performance of NBIX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20

NBIX long term performance overview.The bars show the price performance of NBIX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 -20

The current stock price of NBIX is 110.95 USD. In the past month the price increased by 6.61%. In the past year, price decreased by -22.05%.

NEUROCRINE BIOSCIENCES INC / NBIX Daily stock chart

NBIX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.11 347.17B
AMGN AMGEN INC 13.42 149.80B
VRTX VERTEX PHARMACEUTICALS INC 1740.31 129.75B
GILD GILEAD SCIENCES INC 13.29 128.09B
REGN REGENERON PHARMACEUTICALS 13.7 65.52B
ARGX ARGENX SE - ADR 344.27 39.94B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.91B
ONC BEIGENE LTD-ADR N/A 27.26B
BNTX BIONTECH SE-ADR N/A 24.59B
NTRA NATERA INC N/A 21.56B
SMMT SUMMIT THERAPEUTICS INC N/A 20.79B
BIIB BIOGEN INC 7.74 17.94B

About NBIX

Company Profile

NBIX logo image Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Company Info

NEUROCRINE BIOSCIENCES INC

6027 Edgewood Bend Court

San Diego CALIFORNIA 92130 US

CEO: Kevin C. Gorman

Employees: 1800

NBIX Company Website

NBIX Investor Relations

Phone: 18586177600

NEUROCRINE BIOSCIENCES INC / NBIX FAQ

What is the stock price of NEUROCRINE BIOSCIENCES INC today?

The current stock price of NBIX is 110.95 USD. The price increased by 1.16% in the last trading session.


What is the ticker symbol for NEUROCRINE BIOSCIENCES INC stock?

The exchange symbol of NEUROCRINE BIOSCIENCES INC is NBIX and it is listed on the Nasdaq exchange.


On which exchange is NBIX stock listed?

NBIX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NEUROCRINE BIOSCIENCES INC stock?

32 analysts have analysed NBIX and the average price target is 157.97 USD. This implies a price increase of 42.38% is expected in the next year compared to the current price of 110.95. Check the NEUROCRINE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NEUROCRINE BIOSCIENCES INC worth?

NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of 10.98B USD. This makes NBIX a Large Cap stock.


How many employees does NEUROCRINE BIOSCIENCES INC have?

NEUROCRINE BIOSCIENCES INC (NBIX) currently has 1800 employees.


What are the support and resistance levels for NEUROCRINE BIOSCIENCES INC (NBIX) stock?

NEUROCRINE BIOSCIENCES INC (NBIX) has a support level at 107.62 and a resistance level at 109.69. Check the full technical report for a detailed analysis of NBIX support and resistance levels.


Is NEUROCRINE BIOSCIENCES INC (NBIX) expected to grow?

The Revenue of NEUROCRINE BIOSCIENCES INC (NBIX) is expected to grow by 13.3% in the next year. Check the estimates tab for more information on the NBIX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NEUROCRINE BIOSCIENCES INC (NBIX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NEUROCRINE BIOSCIENCES INC (NBIX) stock pay dividends?

NBIX does not pay a dividend.


When does NEUROCRINE BIOSCIENCES INC (NBIX) report earnings?

NEUROCRINE BIOSCIENCES INC (NBIX) will report earnings on 2025-05-05, after the market close.


What is the Price/Earnings (PE) ratio of NEUROCRINE BIOSCIENCES INC (NBIX)?

The PE ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 33.72. This is based on the reported non-GAAP earnings per share of 3.29 and the current share price of 110.95 USD. Check the full fundamental report for a full analysis of the valuation metrics for NBIX.


What is the Short Interest ratio of NEUROCRINE BIOSCIENCES INC (NBIX) stock?

The outstanding short interest for NEUROCRINE BIOSCIENCES INC (NBIX) is 4.51% of its float. Check the ownership tab for more information on the NBIX short interest.


NBIX Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to NBIX. When comparing the yearly performance of all stocks, NBIX is a bad performer in the overall market: 81.75% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NBIX Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to NBIX. NBIX scores excellent points on both the profitability and health parts. This is a solid base for a good stock.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NBIX Financial Highlights

Over the last trailing twelve months NBIX reported a non-GAAP Earnings per Share(EPS) of 3.29. The EPS increased by 35.95% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.49%
ROA 9.18%
ROE 13.18%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-30.56%
Sales Q2Q%21.84%
EPS 1Y (TTM)35.95%
Revenue 1Y (TTM)24.81%

NBIX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to NBIX. The Buy consensus is the average rating of analysts ratings from 32 analysts.

For the next year, analysts expect an EPS growth of 27.36% and a revenue growth 13.3% for NBIX


Ownership
Inst Owners96.99%
Ins Owners1%
Short Float %4.51%
Short Ratio2.93
Analysts
Analysts83.13
Price Target157.97 (42.38%)
EPS Next Y27.36%
Revenue Next Year13.3%